The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer

Effective drugs are needed for lung cancer, as this disease remains the leading cause of cancer-related deaths. Rexinoids are promising drug candidates for cancer therapy because of their ability to modulate genes involved in inflammation, cell proliferation or differentiation, and apoptosis through...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Sci Rep
Egile Nagusiak: Moerland, Jessica A., Zhang, Di, Reich, Lyndsey A., Carapellucci, Sarah, Lockwood, Beth, Leal, Ana S., Krieger-Burke, Teresa, Aleiwi, Bilal, Ellsworth, Edmund, Liby, Karen T.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7746742/
https://ncbi.nlm.nih.gov/pubmed/33335263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-79260-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak